Athena Athena

X
[{"orgOrder":0,"company":"Deep Genomics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deep Genomics Raises $180M in Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by Deep Genomics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases. Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic.

            Lead Product(s): RNA Therapeutics

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: SoftBank Vision Fund

            Deal Size: $180.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing July 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY